
|Articles|February 1, 2001
- Pharmaceutical Executive-02-01-2001
- Volume 0
- Issue 0
Neurology's Broader Promise: An Exclusive Interview with Christopher Reeve
Author(s)Wayne Koberstein
During our conversation, Reeve pushes an even broader agenda: getting pharmaceutical companies to realize the huge market potential in spinal-cord research for a host of neurological conditions. He implores companies to put their attention, and their investment, into enterprises that are creating breakthroughs in new technologies promising wide therapeutic application.
Advertisement
Articles in this issue
over 25 years ago
The Top Ten Marketing Challenges in Neurologyover 25 years ago
A Right to Dreamover 25 years ago
Woman With a Mission: Pfizer's Lisa Egbuonu-DavisAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5




